Sevoflurane

CHEMBL1200694 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

200.0 g/mol

LogP

2.8

Phase

4

Sevoflurane is a halogenated ether inhalational anesthetic that produces dose-dependent CNS depression through multiple mechanisms including potentiation of GABA-A receptors, inhibition of NMDA receptors, and modulation of two-pore domain potassium channels, used for induction and maintenance of general anesthesia. Its low blood-gas partition coefficient enables rapid onset and offset of anesthesia with smooth induction and recovery properties. It is widely used for outpatient procedures due to its favorable pharmacokinetic profile.

Moleküler Ağırlık

200,0500 g/mol

LogP

2,80

TPSA

9,20 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Glaucoma Cardiovascular Disease Age-Related Macular Degeneration Respiratory Disease Pain Management Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Generalized Anxiety Disorder Melanoma Oncology Gastroesophageal Reflux Disease Inflammatory Bowel Disease Obstetrics & Gynecology Stroke Obesity Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Chronic Pain Atrial Fibrillation Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

FCOC(C(F)(F)F)C(F)(F)F

InChI

InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2

Molecular Formula

C4H3F7O

HBD / HBA

- / 8

Döndürülebilir Bağlar

2

Ağır Atomlar

12

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

Sevoflurane is a halogenated ether inhalational anesthetic that produces dose-dependent CNS depression through multiple mechanisms including potentiation of GABA-A receptors, inhibition of NMDA receptors, and modulation of two-pore domain potassium channels, used for induction and maintenance of general anesthesia. Its low blood-gas partition coefficient enables rapid onset and offset of anesthesia with smooth induction and recovery properties. It is widely used for outpatient procedures due to its favorable pharmacokinetic profile.

Yes, Sevoflurane is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200694. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5206. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Sevoflurane PillFYI'da

Yapı

Hızlı Veriler

Formül: C4H3F7O
Eş Anlamlılar: 8

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.